Amarin Stock Forecast, Price & News

+0.02 (+0.38 %)
(As of 09/23/2021 11:09 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume37,284 shs
Average Volume4.94 million shs
Market Capitalization$2.10 billion
P/E Ratio531.53
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive AMRN News and Ratings via Email

Sign-up to receive the latest news and ratings for Amarin and its competitors with MarketBeat's FREE daily newsletter.

Amarin logo

About Amarin

Amarin Corp. Plc is a biopharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. Its product development program leverages its experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. It has developed and markets Vascepa capsules through wholesale. The company was founded by Geoffrey W. Guy on March 1, 1989 and is headquartered in Dublin, Ireland.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value





Social Links


Overall MarketRank

1.82 out of 5 stars

Medical Sector

767th out of 1,352 stocks

Pharmaceutical Preparations Industry

372nd out of 665 stocks

Analyst Opinion: 3.3Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Amarin (NASDAQ:AMRN) Frequently Asked Questions

Is Amarin a buy right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Amarin in the last twelve months. There are currently 1 sell rating, 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Amarin stock.
View analyst ratings for Amarin
or view top-rated stocks.

What stocks does MarketBeat like better than Amarin?

Wall Street analysts have given Amarin a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Amarin wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Amarin?

Amarin saw a increase in short interest in August. As of August 31st, there was short interest totaling 16,450,000 shares, an increase of 27.1% from the August 15th total of 12,940,000 shares. Based on an average trading volume of 3,780,000 shares, the days-to-cover ratio is currently 4.4 days. Approximately 4.2% of the company's shares are short sold.
View Amarin's Short Interest

When is Amarin's next earnings date?

Amarin is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for Amarin

How were Amarin's earnings last quarter?

Amarin Co. plc (NASDAQ:AMRN) announced its quarterly earnings results on Wednesday, August, 4th. The biopharmaceutical company reported $0.02 earnings per share for the quarter, beating analysts' consensus estimates of ($0.03) by $0.05. The biopharmaceutical company earned $154.50 million during the quarter, compared to analysts' expectations of $153.28 million. Amarin had a trailing twelve-month return on equity of 0.69% and a net margin of 0.70%. The firm's revenue for the quarter was up 14.2% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.04 earnings per share.
View Amarin's earnings history

How has Amarin's stock price been impacted by Coronavirus?

Amarin's stock was trading at $12.56 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, AMRN shares have decreased by 57.7% and is now trading at $5.31.
View which stocks have been most impacted by COVID-19

What price target have analysts set for AMRN?

6 brokerages have issued 1-year target prices for Amarin's shares. Their forecasts range from $5.00 to $19.00. On average, they anticipate Amarin's share price to reach $10.50 in the next twelve months. This suggests a possible upside of 97.7% from the stock's current price.
View analysts' price targets for Amarin
or view top-rated stocks among Wall Street analysts.

Who are Amarin's key executives?

Amarin's management team includes the following people:
  • Karim Mikhail, President, Chief Executive Officer & Director
  • Derek Kalinowski, SVP-Manufacturing Operations
  • Michael W. Kalb, Chief Financial Officer & Senior Vice President (LinkedIn Profile)
  • Steven B. Ketchum, Chief Scientific Officer & Senior Vice President
  • Rebecca Juliano, Senior VP-Clinical Research & Development

What is John Thero's approval rating as Amarin's CEO?

10 employees have rated Amarin CEO John Thero on John Thero has an approval rating of 93% among Amarin's employees. This puts John Thero in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Amarin's key competitors?

What other stocks do shareholders of Amarin own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amarin investors own include Micron Technology (MU), Advanced Micro Devices (AMD), NVIDIA (NVDA), (CGC), Square (SQ), Alibaba Group (BABA), Tesla (TSLA), Bank of America (BAC), Netflix (NFLX) and Novavax (NVAX).

What is Amarin's stock symbol?

Amarin trades on the NASDAQ under the ticker symbol "AMRN."

Who are Amarin's major shareholders?

Amarin's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Jefferies Group LLC (0.00%), SCP Investment LP (1.71%), Morgan Stanley (1.59%), Morgan Stanley (1.59%), Clearbridge Investments LLC (1.21%) and DG Capital Management LLC (1.10%). Company insiders that own Amarin stock include David M Stack, John F Thero, Lars Ekman, Michael Wayne Kalb and Steven B Ketchum.
View institutional ownership trends for Amarin

Which major investors are selling Amarin stock?

AMRN stock was sold by a variety of institutional investors in the last quarter, including Oracle Investment Management Inc., Millennium Management LLC, Renaissance Technologies LLC, Bank of America Corp DE, Susquehanna International Group LLP, Cubist Systematic Strategies LLC, Citadel Advisors LLC, and Edgestream Partners L.P.. Company insiders that have sold Amarin company stock in the last year include John F Thero, Michael Wayne Kalb, and Steven B Ketchum.
View insider buying and selling activity for Amarin
or view top insider-selling stocks.

Which major investors are buying Amarin stock?

AMRN stock was bought by a variety of institutional investors in the last quarter, including Jefferies Group LLC, SCP Investment LP, DG Capital Management LLC, Fairmount Funds Management LLC, Clearbridge Investments LLC, Point72 Asset Management L.P., Simplex Trading LLC, and Jump Financial LLC.
View insider buying and selling activity for Amarin
or or view top insider-buying stocks.

How do I buy shares of Amarin?

Shares of AMRN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Amarin's stock price today?

One share of AMRN stock can currently be purchased for approximately $5.31.

How much money does Amarin make?

Amarin has a market capitalization of $2.10 billion and generates $614.06 million in revenue each year. The biopharmaceutical company earns $-18,000,000.00 in net income (profit) each year or ($0.05) on an earnings per share basis.

How many employees does Amarin have?

Amarin employs 2,020 workers across the globe.

Does Amarin have any subsidiaries?

The following companies are subsidiares of Amarin: Amarin France SAS, Amarin Germany GmbH, Amarin Italy S.r.l, Amarin Pharma Inc., Amarin Pharmaceuticals Ireland Limited, Amarin Switzerland GmbH, Amarin UK Limited, Ester Neurosciences, and Ester Neurosciences Limited.

When was Amarin founded?

Amarin was founded in 1991.

What is Amarin's official website?

The official website for Amarin is

Where are Amarin's headquarters?

How can I contact Amarin?

Amarin's mailing address is 77 Sir John Rogerson`s Quay Block C Grand Canal Docklands, Dublin L2, Dublin 2. The biopharmaceutical company can be reached via phone at (531) 669-9020 or via email at [email protected].

This page was last updated on 9/23/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.